Dare Bioscience, Inc. (DARE) stock
DARENasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.43−0.16 (-26.57%)
Close on Nov 17, 2026Market cap $6.56MP/E –Yield –
Dare Bioscience operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Dare Bioscience's operating cash flow for the twelve months ending Jun 30, 2026 was -$11.29M. For fiscal 2025 it was -$9.89M, down 280.6% from the year before. The highest annual figure on record is $5.47M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.89M | -280.6% |
| FY2024 | Dec 31, 2024 | $5.47M | – |
| FY2023 | Dec 31, 2023 | -$38.86M | – |
| FY2022 | Dec 31, 2022 | -$18.09M | – |
| FY2021 | Dec 31, 2021 | -$28.76M | – |
| FY2020 | Dec 31, 2020 | -$25.23M | – |
| FY2019 | Dec 31, 2019 | -$13.32M | – |
| FY2018 | Dec 31, 2018 | -$10.27M | – |
| FY2017 | Dec 31, 2017 | -$2.54M | – |
| FY2016 | Dec 31, 2016 | -$372.30K | – |
| FY2015 | Dec 31, 2015 | -$31.92M | – |
| FY2014 | Dec 31, 2014 | -$19.06M | – |
| FY2013 | Dec 31, 2013 | -$16.61M | – |
| FY2012 | Dec 31, 2012 | -$21.01M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.78M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.52M | – |
| Q4 FY2025 | Dec 31, 2025 | $1.44M | -72.8% |
| Q3 FY2025 | Sep 30, 2025 | -$442.14K | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.42M | -142.0% |
| Q1 FY2025 | Mar 31, 2025 | -$5.47M | – |
| Q4 FY2024 | Dec 31, 2024 | $5.31M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.92M | – |
| Q2 FY2024 | Jun 30, 2024 | $12.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.81M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.18M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.97M | -192.7% |
| Q2 FY2023 | Jun 30, 2023 | -$6.59M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.12M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.90M | – |
| Q3 FY2022 | Sep 30, 2022 | $8.60M | +551.4% |
| Q2 FY2022 | Jun 30, 2022 | -$8.45M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.34M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.92M | – |
| Q3 FY2021 | Sep 30, 2021 | $1.32M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.79M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.38M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.19M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.36M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.09M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.60M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.81M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.18M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.02M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.31M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.71M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.75M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.69M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.12M | – |
| Q4 FY2017 | Dec 31, 2017 | -$961.07K | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.42M | -105.8% |
| Q2 FY2017 | Jun 30, 2017 | -$109.61K | – |
| Q1 FY2017 | Mar 31, 2017 | -$50.60K | – |
| Q4 FY2016 | Dec 31, 2016 | -$166.95K | – |
| Q3 FY2016 | Sep 30, 2016 | $24.30M | – |
See a number that looks wrong?